Maduck Sean sold $2.9M of CORT

Maduck Sean (See Remarks) sold 25,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $116.26 ($115.54–$116.55, $2.91M total) across 3 trades over 2026-10-01 to 2026-10-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maduck Sean
Published Oct 5, 2026, 11:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 11:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Bearish
high confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTBearishLow
01

Why it matters

The disclosed $2.9M sale reduces insider ownership and may prompt short‑term price weakness, though the pre‑arranged nature tempers the signal.

02

Market read

Primary insider sale; modest impact on CORT's share price, limited broader market effect.

03

What to watch

Potential upcoming clinical data releases or FDA decisions could offset the negative signal from the insider sale.

Relevance 5/10Novelty 7/10Timing: after-hours filing on Oct 5

Background

Form 4 filings disclose insider trades; a 10b5‑1 plan sale by an officer is a routine but noteworthy event for shareholders.

Company-level read

Ticker impact

$CORTBearishHigh confidence
Context

Officer Maduck Sean sold 25,000 shares for $2.9M via a 10b5‑1 plan, reducing his stake to 9,938 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A $2.9M open‑market sale by an officer is a material insider transaction that can trigger short‑term selling pressure.

Market effects

Minimal; the sale is specific to Corcept and does not affect the broader pharma sector.

None; the transaction is company‑specific.

Low; only relevant to investors holding CORT.

Counterpoint

The sale may be purely procedural under a pre‑arranged 10b5‑1 plan and not indicative of future performance.

Key entities

  • Maduck Sean

    Insider who sold 25,000 CORT shares via a 10b5‑1 plan.

  • Corcept Therapeutics Inc.

    Biopharma company whose ticker is CORT.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.